Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Cytovia Therapeutics Inc.
Headquarters: New York, NY, United States of America
Website: https://www.cytoviatx.com/
Year Founded: 2019
Status: Private
BioCentury | Nov 12, 2022
Product Development
Modalities merge into new platforms at SITC 2022
Meeting highlights new platforms combining pieces of cell therapy, bispecific, oncolytic virus and cytokine peptide technologies
BioCentury | Oct 27, 2022
Data Byte
More preclinical companies are going public via reverse merger
Preclinical biotechs are a growing share of the private companies seeking a listing via reverse merger
BioCentury | Apr 29, 2022
Product Development
April 28 Quick Takes: Pfizer enrolling DMD trial after FDA lifts hold
Plus FDA approves AZ’s Ultomiris for gMG and updates from Gilead, Cytovia and more
BioCentury | Mar 30, 2022
Discovery & Translation
iPSC-derived NK cell therapies at AACR22
Presentations highlight gene edits and CAR engineering to improve efficacy of NK cell therapies
BioCentury | Feb 12, 2022
Emerging Company Profile
BioCentury’s 2021 class of emerging cell therapy companies
The 19 newcos are pushing the modality’s frontiers: tapping new cell types, reaching beyond blood cancers and rethinking manufacturing
BioCentury | Nov 4, 2021
Data Byte
Five newcos developing iPS cell-derived therapies for cancer
The biotechs are turning iPS cells into NK, T, B cells and macrophages
BioCentury | Oct 15, 2021
Management Tracks
Malek joins NIBR as head of oncology disease area
Plus: Translate Bio vet Smith joins CRISPR as CFO and updates from Travere, Kojin, AMO, Poseida, Synairgen and more
BioCentury | Jul 30, 2021
Emerging Company Profile
Cytovia: activating NK cells at the tumor site
Emerging Company Profile: With its R&D center up and running and a manufacturing facility by year-end, Cytovia aims to enter the clinic early 2022
BioCentury | Jun 23, 2021
Management Tracks
Bach joining Delfi as CMO; plus Gritstone, Draupnir, Veralox, Cytovia, Avisa and more
BioCentury | Jun 17, 2021
Management Tracks
Syncona expands C-suite; plus Myriad, Aulos, Cytovia, Elevation and more
Syncona Ltd. (LSE:SYNC) hired Rolf Soderstrom as CFO, Markus John as CMO and head of R&D and Fiona Langton-Smith as chief human resources officer. Soderstrom, who previously served as CFO of BTG
Items per page:
1 - 10 of 15